Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Galectin's GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
http://investor.galectintherapeutics.com/releasedetail.cfm?ReleaseID=1016012
Glickman will speak on Monday (3/6) at 1:20 PM at the Cowen Healthcare Conference. I will sure be listening into that. Have a great weekend!
WGBS- WaferGen Biosystems * Security Deletion added to the halt for this equity.
PTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren in Patients Living with Nonsense Mutation Cystic Fibrosis
- ACT CF trial missed primary and secondary endpoints -
- Company to host conference call today, March 2nd at 9:00 am ET -
http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=1015471
Haha. Good stuff Vid
very impressive!!
The data lands
Dr. Richard Mulligan to head biotech for Carl Icahn (for all you Sarissa Capital groupies)
https://globenewswire.com/news-release/2017/03/01/929518/0/en/Icahn-Enterprises-L-P-Announces-Hiring-of-Dr-Richard-C-Mulligan.html
WGBS- WaferGen Biosystems t-12 Halt.
Nasdaq has requested more info from the company
NDRM HALTED.
NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting
http://ir.neuroderm.com/phoenix.zhtml?c=253749&p=irol-newsArticle&ID=2250523
Impressive company :)
back in GLUU after a few years away. Like returning to an old friend. GLTA
JP- I own some AUPH, haven't added the other A's yet. About that tech company you mentioned I was thinking the same. maybe just hold a bundle of shares for a potential buyout or the day they actually figure out how to monetize the millions and millions using it. GLTA
Maybe news after hours today nice to see nonetheless
Nice Vid. Good luck.
As I was telling vid. I'm happy with my position in AUPH considering the proportion of funds reinvested from ARIA. Holding through data is lower stress compared to ariad's 2015 fluctuations. Especially the times ariad released great news to have the stock be neutral or red in the response.
I agree that this company is on to something and it's early. Could be huge in a few years.
Any positive AF piece is always a surprise But yes it was pretty balanced and he had a one on one with huizinga out in CA recently
Reminds me of those ariad days. Big moves were just part of the trading pattern and never amounted to anything but a climb higher
Haha. I took his 10 year reference as him making a joke about how everyone should take a 10 year recharger.
Take it easy on him. He's working with the Holy Grail! :)
According to SAGE CEO they are on the top of everyone's M&A list. Or.... the company response link-->
http://investor.sagerx.com/releasedetail.cfm?ReleaseID=1012358
Speaking of Sarissa's holdings updates, while looking into their unloading of ARRY, I noticed that they initiated a new position in a respiratory assets company called Innoviva (INVA) in Sept 2016, and now have upped their stake to nearly 3 million shares (a 200% increase from the first position). INVA has some partnerships with GSK at the moment... Figured that was worth a mention since the INVA board seems dead.
I don't see it returning to the 8's like we saw in mid January. Sarissa or not, this company still has a lot going for it. I agree with Vid on its buyout potential, even without a takeout, the pipeline here is getting very interesting for catalysts.
anyone listen to the AUPH leerink talk today? impressive stuff. I am in AUPH and waiting to buy here soon
I enjoyed todays Leerink call. Glickman found is comfort zone quickly in the new CEO role Loved the Holy Grail references, On a serious note I felt Glickman addressed the mortality in the studies well. Theres a very strong chance that AUPH finds a partner and accesses non-dilutive financing, a nice touch. We are all anticipating the 48 week data. Biotech is never boring. GLTA
I would love a healthy pullback at the moment so I can get a few thousand shares under 10. but it probably won't happen
FDA approves Siliq--> Valeant's drug to treat plaque psoriasis
http://www.nasdaq.com/article/fda-approves-valeants-drug-to-treat-plaque-psoriasis-20170215-01599
I did my best with chineseinvestors.com website. Didn't understand any of it lol
I think we won't get the data tomorrow. Glickman will do the fireside chat with a review of the company's activities as well as the Japan profile potential. I think data will be out at end of the month
It is concerning However sarissa isn't the only game in town. Maybe he felt it was time to unload aside from company events. Great prospects for this company. I have no position yet. Kinda kickin myself for not buying some back in the 8's.
I wonder why? This company has rocked 2017. To be continued I guess
Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin
Data support continued development of voclosporin in the Japanese patient population
http://ir.auriniapharma.com/press-releases/detail/72
Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin
DOWNLOAD AS PDF FEBRUARY 14, 2017
Data support continued development of voclosporin in the Japanese patient population
http://ir.auriniapharma.com/press-releases/detail/72
Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
http://gilead.com/news/press-releases/2017/2/gilead-announces-findings-from-new-preclinical-study-evaluating-novel-class-of-hiv-capsid-inhibitors
Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
http://gilead.com/news/press-releases/2017/2/gilead-presents-new-phase-2-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv
Great day here price wise. Don't forget the fireside chat at Leerink conference feb 16th. Will we see 48week data tomorrow?
Negative. He has a house on a few acres. His main squeeze lives in pleasant valley so he's down there a lot as well.
AACR17 abstract titles are available for your viewing pleasure below link
http://www.abstractsonline.com/pp8/#!/4292
Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis
Company to host investor conference call today at 8:30 a.m. ET
NEW YORK, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will provide an update on the Phase 3 REGENERATE trial of obeticholic acid (OCA) in NASH patients with liver fibrosis during a conference call today, Friday February 10 at 8:30 a.m. ET.
Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors
-Seattle Genetics to Lead Development, Manufacturing and Commercialization of Sacituzumab Govitecan Globally-
http://www.businesswire.com/news/home/20170210005287/en/Seattle-Genetics-Announces-Global-License-Agreement-Immunomedics
I assume you aren't a CRISPR fan either vid? I showed my dad (retired physician) some data on that stuff he had the same response that you gave Jess :)
ARRY is rocketing today congrats!
Btw my dad just moved to millbrook. I have a feeling you know where that is.
You might be correct. However this may be a false bottom. I still concerned with regional copy cats and WFM lack of exclusivity and I want Mackey to step aside. He's tired and I'm tired of him acting like he is fresh
Wfm is gonna rev up the prepared foods themes. Will take time and renovations like what Philly has done to see the returns. Great comp potential. How tech savvy are they will assist their resurgence. Wfm has a habit of being in Atari mode with tech Until then I'm not a super Bull
I do like wfm btw. Just frustrated with what I have seen in my market area here in western pa and my research